Age-related macular degeneration and recent developments: new hope for old eyes?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the commonest cause of blindness in the population over 60 years of age and accounts for over 50% of those registered blind in the UK. The incidence is increasing and as older generations live longer a growing number of patients will be affected in the future. Affected patients lose central vision, important in all aspects of everyday life. This review outlines risk factors for AMD, clinical features, treatment and management strategies for patients, families and physicians caring for those with AMD. Recent trials are included along with practical clinical advice. While there is no curative treatment at present, intervention can reduce the risk of developing AMD and limit disease progression if it occurs. These modalities are discussed here. As new discoveries in the field of genetics and novel therapies emerge, a brighter future seems certain for the ageing population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration
Seddon, J. M. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520180037032 · Cited by 993
Risk factors for incident age-related macular degeneration
Tomany, S. C., Wang, J. J., van Leeuwen, R., Klein, R., Mitchell, P., Vingerling, J. R., Klein, B. E. K., Smith, W., & de Jong, P. T. V. M. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.11.010 · Cited by 621
A prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Seddon, J. M. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1728 · Cited by 384
Missense Variations in the Fibulin 5 Gene and Age-Related Macular Degeneration
Stone, E. M., Braun, T. A., Russell, S. R., Kuehn, M. H., Lotery, A. J., Moore, P. A., Eastman, C. G., Casavant, T. L., & Sheffield, V. C. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040833 · Cited by 324
A Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320
Cited by
Lavanya, R., Jeganathan, V. S. E., Zheng, Y., Raju, P., Cheung, N., Tai, E. S., Wang, J. J., Lamoureux, E., Mitchell, P., Young, T. L., et al. (2009) · Ophthalmic Epidemiology · doi:10.3109/09286580903144738 · Cited by 322
Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations
Short, B. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310955 · Cited by 244
Jain, A., Chea, S., Matsumiya, W., Halim, M. S., Yaşar, Ç., Kuang, G., Sepah, Y. J., Khanani, A. M., Do, D. V., & Nguyen, Q. D. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100687 · Cited by 109
Cackett, P., Wong, T. Y., Aung, T., Saw, S.-M., Tay, W. T., Rochtchina, E., Mitchell, P., & Wang, J. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.06.026 · Cited by 87
Metadata
- Authors
- Morris, B., Imrie, F., Armbrecht, A.-M., & Dhillon, B.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 83
- Issue
- 979
- Pages
- 301-307
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2051770135
- Cited by
- 48
- References
- 13
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.